Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering treatments for the significant unmet medical needs of targeted patient populations affected by autoimmune, kidney, and rare diseases. In January 2021, the company launched LUPKYNIS® (voclosporin), the first oral therapy approved by the U.S. Food and Drug Administration specifically for the treatment of adult patients with active lupus nephritis.